Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
Conditions
Interventions
Selinexor
Dexamethasone Oral
+2 more
Locations
10
United States
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Maryland Oncology Hematology, P.A.
Columbia, Maryland, United States
New York Oncology Hematology, P.C.
Albany, New York, United States
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
Texas Oncology, P.A.
Austin, Texas, United States
Start Date
September 10, 2021
Primary Completion Date
May 31, 2026
Completion Date
May 31, 2026
Last Updated
January 16, 2025
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06870760
NCT06057402
Lead Sponsor
US Oncology Research
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions